Altamira Therapeutics, a Swiss-based drug researcher focussing RNA therapeutics, allergy and viral infections and inner ear disorders, said that it has completed the patient enrolment in its Bentrio trial in house dust mite allergic rhinitis. The trials are to evaluate the efficacy of Bentrio– its nasal spray that helps protect against airborne viruses and allergens – – in 37 patients with a history of perennial allergic rhinitis caused by HDM exposure, where the participants will be randomised under an open label, three-period crossover design to receive either Bentrio in a single or double dose or no treatment prior to HDM exposure for three hours. The current study tries to demonstrate Bentrio’s protective effects against multiple airborne allergens.